NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Forecast, Price & News $7.59 -0.16 (-2.06%) (As of 11:39 AM ET) Add Compare Share Share Today's Range$7.56▼$7.7450-Day Range$7.55▼$10.2352-Week Range$4.77▼$14.34Volume46,620 shsAverage Volume453,750 shsMarket Capitalization$333.20 millionP/E Ratio3.34Dividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Voyager Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside119.4% Upside$17.00 Price TargetShort InterestBearish5.73% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.75Based on 8 Articles This WeekInsider TradingSelling Shares$145,080 Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.11 to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector280th out of 969 stocksBiological Products, Except Diagnostic Industry43rd out of 162 stocks 3.3 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Voyager Therapeutics has a forecasted upside of 119.4% from its current price of $7.75.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.73% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Voyager Therapeutics has recently decreased by 3.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 77.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.62. Previous Next 2.6 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Voyager Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows86 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $145,080.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions58.81% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from $1.11 to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 3.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 107.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 3.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.71.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Voyager Therapeutics (NASDAQ:VYGR) StockVoyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.Read More VYGR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesSeptember 30, 2023 | msn.comGerman Bike Brand Möve Presents New Voyager V10 Commuter E-BikeSeptember 28, 2023 | msn.comThe 10 best Star Trek: Voyager episodes, rankedOctober 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.September 27, 2023 | tmcnet.comFormer Chief Scientist of the United States Air Force Dr. Mark J. Lewis Appointed to Voyager Space Advisory BoardSeptember 26, 2023 | yahoo.comVoyager educator named to Michigan Teacher Leadership CollaborativeSeptember 25, 2023 | msn.comCorsair's Voyager gaming laptop is now $1,200 offSeptember 25, 2023 | finance.yahoo.comVoyager Therapeutics to Present at the Chardan Genetic Medicines ConferenceSeptember 24, 2023 | msn.comAssessing Voyager's Alzheimer's Treatment PotentialOctober 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.September 22, 2023 | msn.comCorsair’s Voyager a1600 Gaming Laptop comes with a Ryzen R7 chip and 48 percent savingsSeptember 22, 2023 | msn.comVoyager's lead singer Danny Estrin reveals cancer diagnosis and cancels European tourSeptember 21, 2023 | msn.comVoyager Lead Singer Danny Estrin Diagnosed with CancerSeptember 21, 2023 | au.lifestyle.yahoo.comVoyager's Danny Estrin shares 'devastating' cancer diagnosisSeptember 21, 2023 | yahoo.comVoyager postpone October European tour in wake of Danny Estrin's shock cancer diagnosisSeptember 21, 2023 | news.yahoo.comVoyager’s Danny Estrin, who represented Australia in Eurovision 2023, shares ‘life-altering news’September 19, 2023 | msn.comStar Trek: Fans Will Never Forgive Voyager For This Missed OpportunitySeptember 18, 2023 | msn.comOn this date: Voyager’s first amazing photo (of Many)September 16, 2023 | msn.comHistoric space photo of the week: Voyager 2 spies a storm on Saturn 42 years agoSeptember 11, 2023 | msn.comBlue Star’s new non-executive director is a helium market insider ready to steer Voyager towards first productionSeptember 8, 2023 | au.investing.comBlue Star Helium upgrades Voyager well design to further optimise recoverySeptember 5, 2023 | msn.comBGSU student is honored as national Obama-Chesky Voyager ScholarAugust 29, 2023 | yahoo.comPowder Review: Moment Voyager XV Evo BindingAugust 25, 2023 | forbes.com100 New Recipients Of The Obama-Chesky Voyager Scholarship Are AnnouncedAugust 21, 2023 | yahoo.comVoyager Announce 2024 National ‘Fearless in Love’ TourAugust 19, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 43% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)August 8, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)August 8, 2023 | msn.comOppenheimer Reiterates Voyager Therapeutics (VYGR) Outperform RecommendationSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Company Calendar Last Earnings8/03/2023Today10/02/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$18.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+119.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.27 Trailing P/E Ratio3.41 Forward P/E Ratio6.98 P/E GrowthN/ANet Income$-46,410,000.00 Net MarginsN/A Pretax Margin49.58% Return on Equity69.09% Return on Assets38.58% Debt Debt-to-Equity RatioN/A Current Ratio6.22 Quick Ratio6.22 Sales & Book Value Annual Sales$40.91 million Price / Sales8.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book5.07Miscellaneous Outstanding Shares43,900,000Free Float41,838,000Market Cap$340.23 million OptionableOptionable Beta1.03 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 65)M.D., Ph.D., Pres, CEO & Director Comp: $825.41kMr. Peter P. Pfreundschuh CPA (Age 54)Chief Financial Officer Comp: $172.73kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 64)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMs. Robin Swartz (Age 52)Chief Operating Officer Mr. Todd Carter Ph.D. (Age 53)Chief Scientific Officer Ms. Jacquelyn Fahey Sandell Esq.J.D., Chief Legal OfficerMs. Michelle Quinn SmithChief HR OfficerMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEMonte Rosa TherapeuticsNASDAQ:GLUEMeiraGTxNASDAQ:MGTXCoherus BioSciencesNASDAQ:CHRSHumacyteNASDAQ:HUMAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 29,097 shares on 9/21/2023Ownership: 0.014%Todd Alfred CarterSold 10,500 sharesTotal: $85,680.00 ($8.16/share)California State Teachers Retirement SystemBought 10,565 shares on 8/21/2023Ownership: 0.024%Nuveen Asset Management LLCBought 88,425 shares on 8/16/2023Ownership: 0.201%Lazard Asset Management LLCBought 10,260 shares on 8/15/2023Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions VYGR Stock - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price forecast for 2023? 3 analysts have issued 12-month price targets for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 119.4% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2023? Voyager Therapeutics' stock was trading at $6.10 at the beginning of the year. Since then, VYGR stock has increased by 27.0% and is now trading at $7.75. View the best growth stocks for 2023 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.08. The company had revenue of $4.85 million for the quarter, compared to analyst estimates of $2 million. What ETF holds Voyager Therapeutics' stock ? iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $7.75. How much money does Voyager Therapeutics make? Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $340.23 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.27 on an earnings per share basis. How many employees does Voyager Therapeutics have? The company employs 125 workers across the globe. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com. This page (NASDAQ:VYGR) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.